In This Issue

Bardoxolone methyl has been considered a potential therapy for several types of kidney disease because it activates a cytoprotective factor and inhibits a proinflammatory factor. In the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial, bardoxolone was tested in patients with diabetic nephropathy and advanced chronic kidney disease (CKD) and was found to improve estimated glomerular filtration rate (eGFR); however, it also increased albuminuria.
Source: Kidney International - Category: Urology & Nephrology Tags: In This Issue Source Type: research